Clincosm LogoSign in Get a demo

Emotional Intelligence in Schizophrenia and Bipolar-I- Disorder

Sponsor
Medical University Innsbruck (Other)
Overall Status
Completed
CT.gov ID
NCT01998516
Collaborator
Paracelsus Medical University (Other), Austrian Science Fund (FWF) (Other)
350
Enrollment
1
Location
44
Duration (Months)
8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Scientific Background

Emotional Intelligence (EI) as a part of social cognition is a rather new area of interest which focuses on personality traits and abilities enabling people to cope with both their own feelings as well as those of others. The "Mayer-Salovey-Caruso-Emotional-Intelligence-Test" (MSCEIT) (1) represents a valid and reliable instrument which exclusively covers the emotional components of social cognition. Recent findings indicate, that social cognitive impairments are useful vulnerability indicators and that EI could be an endophenotype for schizophrenia and bipolar I disorder (BD I). To confirm the endophenotype theory, studies concerning EI in relatives of schizophrenia and bipolar patients are needed. To date, studies on EI in BD patients as well as in first degree relatives of patients with schizophrenia or BD haven't been conducted yet. Accordingly, the current study focuses on the four categories assessed by the MSCEIT and aims to compare the task performance of patients, their first degree relatives and healthy control subjects. We assume that the task performance of relatives lies between that of patients and controls. The confirmation of this assumption would verify the trait marker hypothesis and could be a next step to identify a heritable endophenotype for schizophrenia and BD.

Hypotheses

Compared to healthy control subjects patients suffering from schizophrenia or BD I show deficits in EI. Siblings of patients with schizophrenia or BD I show deficits in EI and their task performance lies between that of patients and healthy controls. Deficits in EI are more pronounced in schizophrenia patients than in patients with BD I and are more pronounced in siblings of schizophrenia patients than in siblings of patients with BD I. Independently of diagnosis, deficits in EI affect patients' functional and subjective outcomes.

Methods

Emotional Intelligence will be examined using the MSCEIT in patients with schizophrenia, siblings of schizophrenia patients, patients with BD I, siblings of BD I patients and healthy volunteers matched for age, sex, and educational level. Structured clinical interviews according to DSM-IV (M.I.N.I. + SCID II) will be carried out to assure the diagnosis of schizophrenia or bipolar disorder as well as to detect (comorbid) Axis I and Axis II psychiatric disorders (patients, siblings, control subjects). Functional outcome will be assessed by using the GAF (Global Assessment of Functioning Scale) and the PSP (Personal and Social Performance Scale), subjective quality of life will be examined using the BELP (Berliner Lebensqualiätsprofil). The MWT-B (Multiple choice vocabulary test) will be used to assess premorbid intelligence.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    350 participants
    Observational Model:
    Other
    Time Perspective:
    Cross-Sectional
    Official Title:
    Emotional Intelligence in Schizophrenia and Bipolar I Disorder: a Comparison Between Patients, Their Siblings, and Healthy Controls
    Study Start Date :
    Dec 1, 2013
    Actual Primary Completion Date :
    Dec 31, 2016
    Actual Study Completion Date :
    Jul 31, 2017

    Arms and Interventions

    Arm Intervention/Treatment
    Schizophrenia Patients
    Bipolar I Patients
    Siblings of Schizophrenia Patients
    Siblings of Bipolar I Patients
    Healthy Controls

    Outcome Measures

    Primary Outcome Measures

    1. Emotional Intelligence [24 month]

      Assessed with the MSCEIT (Mayer-Salovey-Caruso-Emotional-Intelligence-Test

    Secondary Outcome Measures

    1. Quality of Life [24 month]

      Assessed with the Lancashire Quality of Life Profile

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • ICD-10 diagnosis of schizophrenia or BD (verified by Mini International Neuropsychiatric Interview (M.I.N.I.)

    • Outpatients with stable psychopathology for at least half a year and fixed treatment regimen for at least one month prior to testing

    • Age: 18-65 years

    • Native German Speakers

    • Written informed consent

    Exclusion Criteria:

    • Other axis 1 disorder (verified by M.I.N.I.)

    • History of organic mental disorder

    • Mental Retardation

    • Epilepsy

    • Pregnancy/breast-feeding

    • Unstable and/or severe organ system diseases, e.g. cardiovascular, endocrine, metabolic

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Medical University Innsbruck Innsbruck Austria 6020

    Sponsors and Collaborators

    • Medical University Innsbruck
    • Paracelsus Medical University
    • Austrian Science Fund (FWF)

    Investigators

    • Principal Investigator: Alex Hofer, Assoc. Prof. Dr., Medical University Innsbruck

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Assoc. Prof. Dr. Alex Hofer, Assoc. Prof. Dr., Medical University Innsbruck
    ClinicalTrials.gov Identifier:
    NCT01998516
    Other Study ID Numbers:
    • KLI 366
    First Posted:
    Nov 29, 2013
    Last Update Posted:
    Sep 20, 2017
    Last Verified:
    Sep 1, 2017
    Keywords provided by Assoc. Prof. Dr. Alex Hofer, Assoc. Prof. Dr., Medical University Innsbruck
    Emotional Intelligence
    Additional relevant MeSH terms:
    Schizophrenia

    Study Results

    No Results Posted as of Sep 20, 2017